Agios Pharmaceuticals, Inc. (AGIO)
Trading disclosure
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for certain activity generated through this link. Prices displayed are informational.
Learn moreKey Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
|
Mr. Brian M. Goff M.B.A.
|
CEO & Director | 1.45M | -- | 1969 |
|
Ms. Cecilia Jones
|
Chief Financial Officer | 791.84k | -- | 1975 |
|
Dr. Krishnan Viswanadhan M.B.A., Pharm.D.
|
Chief Strategy & Operations Officer | 931.51k | -- | 1979 |
|
Mr. James William Burns
|
Chief Legal Officer | 780.51k | -- | 1978 |
|
Dr. Sarah Gheuens M.D., Ph.D.
|
Chief Medical Officer and Head of Research & Development | 887.23k | 266.94k | 1980 |
|
Dr. Lewis clayton Cantley Ph.D.
|
Co-Founder | 50k | -- | 1949 |
|
Dr. Tak Wah Mak D.Sc., FRSC, Ph.D.
|
Co-Founder | -- | -- | 1946 |
|
Dr. Craig B. Thompson M.D.
|
Co-Founder | -- | -- | 1953 |
|
Dr. Shin-San Su Ph.D.
|
Co-Founder | -- | -- | 1956 |
|
Mr. T. J. Washburn
|
VP, Controller & Principal Accounting Officer | -- | -- | 1982 |
Agios Pharmaceuticals, Inc.
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 539
Description
Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes used for the treatment of hemolytic anemias in adults with PK deficiency. The company's PYRUKYND product is also used for the treatment of sickle cell disease that is in phase 3 clinical trial; for the treatment of PK deficiency in pediatric patients; and AQVESME for the treatment of adult patients with non-transfusion dependent and transfusion-dependent alpha- or beta-thalassemia. In addition, it developed tebapivat, a PK activator for the treatment of lower-risk myelodysplastic syndrome and sickle cell disease; AG-181, a phenylalanine hydroxylase stabilizer for the treatment of phenylketonuria (PKU); and AG-236, an siRNA in-licensed from Alnylam, targeting the transmembrane serine protease 6 (TMPRSS6) gene for the treatment of polycythemia vera. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.
Corporate Governance
Upcoming Events
November 5, 2026 at 12:30 PM UTC
Agios Pharmaceuticals, Inc. Earnings Date
